In one of the largest M&A deals of 2020 so far, Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals for US$6.5 B. With the deal, J&J gains access to Momenta’s lead asset, nipocalimab, a Phase II/III candidate for the treatment of warm antibody haemolytic anaemia, as well as M254, CSL-partnered M230, and M267, a preclinical CD38 SIFbody programme. The buyout comes just two years after Momenta exited the biosimilar drug development space to focus on developing its drug candidates for immune-mediated diseases.